CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade PDS Biotechnology Corporation - PDSB CFD

5.18
1.71%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

PDS Biotechnology Corp ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 5.27
Open* 5.28
1-Year Change* 60.98%
Day's Range* 5.12 - 5.28
52 wk Range 2.89-13.65
Average Volume (10 days) 361.09K
Average Volume (3 months) 14.04M
Market Cap 182.74M
P/E Ratio -100.00K
Shares Outstanding 30.87M
Revenue N/A
EPS -1.61
Dividend (Yield %) N/A
Beta 1.92
Next Earnings Date Nov 13, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 22, 2023 5.18 -0.03 -0.58% 5.21 5.28 5.11
Sep 21, 2023 5.27 0.04 0.76% 5.23 5.34 5.15
Sep 20, 2023 5.25 -0.08 -1.50% 5.33 5.47 5.18
Sep 19, 2023 5.31 -0.04 -0.75% 5.35 5.48 5.27
Sep 18, 2023 5.36 0.00 0.00% 5.36 5.55 5.31
Sep 15, 2023 5.30 -0.20 -3.64% 5.50 5.53 5.27
Sep 14, 2023 5.58 0.05 0.90% 5.53 5.73 5.44
Sep 13, 2023 5.46 -0.12 -2.15% 5.58 5.81 5.45
Sep 12, 2023 5.55 -0.13 -2.29% 5.68 5.82 5.53
Sep 11, 2023 5.87 0.17 2.98% 5.70 5.99 5.68
Sep 8, 2023 5.79 0.00 0.00% 5.79 5.88 5.76
Sep 7, 2023 5.88 0.12 2.08% 5.76 5.96 5.70
Sep 6, 2023 5.80 -0.01 -0.17% 5.81 5.86 5.59
Sep 5, 2023 5.78 -0.16 -2.69% 5.94 5.98 5.75
Sep 1, 2023 6.01 0.18 3.09% 5.83 6.12 5.83
Aug 31, 2023 5.84 -0.11 -1.85% 5.95 6.00 5.80
Aug 30, 2023 5.94 0.02 0.34% 5.92 5.99 5.85
Aug 29, 2023 5.94 -0.39 -6.16% 6.33 6.33 5.81
Aug 28, 2023 6.37 0.48 8.15% 5.89 6.47 5.88
Aug 25, 2023 5.94 0.09 1.54% 5.85 6.03 5.71

PDS Biotechnology Corporation Events

Time (UTC) Country Event
Monday, November 13, 2023

Time (UTC)

13:30

Country

US

Event

Q3 2023 PDS Biotechnology Corp Earnings Release
Q3 2023 PDS Biotechnology Corp Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Revenue 0
Total Operating Expense 41.6724 21.4393 14.9024 7.70005 43.0966
Selling/General/Admin. Expenses, Total 12.2414 10.1848 6.96233 8.91149 15.0205
Research & Development 29.431 11.2545 7.92445 6.09958 16.0688
Operating Income -41.6724 -21.4393 -14.9024 -7.70005 -43.0966
Interest Income (Expense), Net Non-Operating -0.38134 0.00435 0.05501 0.31993 -0.55338
Other, Net 0 0
Net Income Before Taxes -42.0538 -21.435 -14.8474 -7.38012 -43.6499
Net Income After Taxes -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Net Income Before Extra. Items -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Net Income -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Income Available to Common Incl. Extra. Items -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Diluted Net Income -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Diluted Weighted Average Shares 28.5992 25.5971 16.745 4.86808 1.56211
Diluted EPS Excluding Extraordinary Items -1.42853 -0.66095 -0.88667 -1.43765 -26.1621
Diluted Normalized EPS -1.42853 -0.66095 -0.85692 -2.41384 -21.1658
Total Extraordinary Items 0
Unusual Expense (Income) 0 -7.31102 12.0073
Depreciation / Amortization 0.01561 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 12.6962 9.42241 18.8214 7.2792 7.09265
Selling/General/Admin. Expenses, Total 4.69132 3.57873 2.66627 2.92621 3.33101
Research & Development 8.00485 5.84369 16.1551 4.35299 3.76165
Operating Income -12.6962 -9.42241 -18.8214 -7.2792 -7.09265
Interest Income (Expense), Net Non-Operating -0.24475 -0.23751 -0.14525 0.07455
Net Income Before Taxes -12.9409 -9.65992 -19.1377 -7.42445 -7.01811
Net Income After Taxes -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
Net Income Before Extra. Items -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
Net Income -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
Income Available to Common Excl. Extra. Items -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
Income Available to Common Incl. Extra. Items -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
Diluted Net Income -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
Diluted Weighted Average Shares 30.8025 30.428 29.0379 28.4587 28.4516
Diluted EPS Excluding Extraordinary Items -0.37448 -0.31747 -0.65906 -0.26089 -0.20453
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.37448 -0.31747 -0.65906 -0.26089 -0.20453
Other, Net -0.31633
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 76.4804 66.8402 30.3372 14.4702 35.6511
Cash and Short Term Investments 73.8202 65.2426 28.8396 12.1617 34.6455
Cash & Equivalents 73.8202 65.2426 28.8396 12.1617 34.6455
Prepaid Expenses 2.66023 1.59757 1.49767 2.30846 1.00559
Total Assets 77.0079 67.1979 30.8904 14.4913 36.221
Property/Plant/Equipment, Total - Net 0.52753 0.3577 0.55315 0.02105 0.42695
Property/Plant/Equipment, Total - Gross 0.64295 0.47303 0.66313 0.11542 0.87862
Accumulated Depreciation, Total -0.11542 -0.11533 -0.10998 -0.09437 -0.45166
Other Long Term Assets, Total 0 0.14287
Total Current Liabilities 9.82104 3.75603 3.27045 2.79355 6.38175
Accounts Payable 1.21929 1.3094 1.41522 1.19772 0.39945
Accrued Expenses 8.54514 2.44663 1.85523 1.09764 0.38616
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.05661 0
Other Current Liabilities, Total 0 0.49819 5.59614
Total Liabilities 33.0059 3.98746 3.7608 2.79355 6.38175
Total Long Term Debt 23.1849 0 0 0 0
Long Term Debt 23.0208 0 0
Total Equity 44.002 63.2104 27.1296 11.6977 29.8392
Common Stock 0.00996 0.00939 0.00735 0.00174 0.01059
Additional Paid-In Capital 145.55 123.905 70.9073 40.6337 222.645
Retained Earnings (Accumulated Deficit) -101.558 -60.7036 -43.7851 -28.9377 -192.816
Total Liabilities & Shareholders’ Equity 77.0079 67.1979 30.8904 14.4913 36.221
Total Common Shares Outstanding 30.1703 28.4486 22.2616 5.28124 1.5725
Preferred Stock - Non Redeemable, Net 0
Other Liabilities, Total 0 0.23143 0.49035 0
Capital Lease Obligations 0.16401
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 67.9734 76.4804 74.4113 55.7426 60.7305
Cash and Short Term Investments 65.1994 73.8202 71.6424 52.9847 58.8811
Cash & Equivalents 65.1994 73.8202 71.6424 52.9847 58.8811
Prepaid Expenses 2.77399 2.66023 2.76891 2.75791 1.84941
Total Assets 68.4486 77.0079 74.8868 56.0008 61.0388
Property/Plant/Equipment, Total - Net 0.47526 0.52753 0.47542 0.25819 0.30833
Total Current Liabilities 4.12954 9.82104 4.84114 4.51592 5.01849
Accounts Payable 2.07206 1.21929 2.03739 1.87799 2.74571
Accrued Expenses 2.00537 8.54514 2.74248 2.63793 2.27278
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 27.4377 33.0059 27.8279 4.57557 5.16547
Total Long Term Debt 23.3081 23.1849 22.9868 0 0
Other Liabilities, Total 0 0 0.05965 0.14698
Total Equity 41.0109 44.002 47.0588 51.4252 55.8734
Common Stock 0.01014 0.00996 0.00939 0.00939 0.00939
Additional Paid-In Capital 152.219 145.55 129.47 126.412 125.041
Retained Earnings (Accumulated Deficit) -111.218 -101.558 -82.4207 -74.9963 -69.1771
Total Liabilities & Shareholders’ Equity 68.4486 77.0079 74.8868 56.0008 61.0388
Total Common Shares Outstanding 30.7236 30.1703 28.4587 28.4587 28.4509
Current Port. of LT Debt/Capital Leases 0.05211 0.05661 0.06127
Long Term Debt 23.1428 23.0208 22.9097
Capital Lease Obligations 0.16529 0.16401 0.07713
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Cash From Operating Activities -25.7097 -12.4861 -13.1491 -18.0735 -33.1533
Cash From Operating Activities 0.04908 0.00536 0.01561 0.09841 0.17435
Non-Cash Items 10.6211 4.35124 0.61297 -6.22017 10.9689
Cash Interest Paid 0.85222 0 1.05117
Changes in Working Capital 4.47498 0.07582 1.06967 -4.5716 -3.4285
Cash From Investing Activities 0 29.3815 0
Capital Expenditures 0
Cash From Financing Activities 34.2872 48.8891 29.827 0.75 -20.2688
Financing Cash Flow Items -0.72029 -0.99
Issuance (Retirement) of Stock, Net 10.0075 48.8891 29.827 0.75 0.7212
Issuance (Retirement) of Debt, Net 25 0 -20
Net Change in Cash 8.57754 36.4031 16.6778 12.058 -53.4221
Deferred Taxes 0 -0.38151
Cash Taxes Paid 0
Other Investing Cash Flow Items, Total 0 29.3815
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -9.65992 -40.8549 -21.7172 -14.2927 -8.47352
Cash From Operating Activities -13.1886 -25.7097 -18.1808 -12.2879 -6.36901
Cash From Operating Activities 0.01411 0.04908 0.0375 0.00009 0.00009
Non-Cash Items 2.26257 10.6211 4.07542 2.59809 1.18923
Changes in Working Capital -5.8054 4.47498 -0.57652 -0.59332 0.9152
Cash From Financing Activities 4.56786 34.2872 24.5806 0.02992 0.00749
Issuance (Retirement) of Stock, Net 4.58852 10.0075 0.02992 0.02992 0.00749
Net Change in Cash -8.62078 8.57754 6.39982 -12.2579 -6.36152
Cash Interest Paid 0.96685 0.85222 0.0625
Financing Cash Flow Items -0.72029 -0.44933
Issuance (Retirement) of Debt, Net -0.02067 25 25

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

PDS Biotechnology Corporation Company profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Industry: Bio Therapeutic Drugs

25B Vreeland Road
Suite 300
FLORHAM PARK
NEW JERSEY 07932
US

Income Statement

  • Annual
  • Quarterly

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

ETH/USD

1,594.77 Price
+0.030% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

BTC/USD

26,619.15 Price
+0.140% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

US100

14,710.90 Price
+0.190% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 7.0

Oil - Crude

90.14 Price
+0.770% 1D Chg, %
Long position overnight fee 0.0415%
Short position overnight fee -0.0634%
Overnight fee time 21:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading